FOXQ1 and cholangiocarcinoma: Differential analysis in TCGA indicated that compared with normal tissues, FOXQ1 was upregulated in cholangiocarcinoma, colon adenocarcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, rectum adenocarcinoma, thyroid carcinoma, and uterine corpus endometrial carcinoma and downregulated in glioblastoma multiforme, kidney chromophobe, kidney renal clear cell carcinoma, and prostate adenocarcinoma (Figure 1A).